The latest price target for Syndax Pharmaceuticals (NASDAQ:SNDX) was reported by Scotiabank on January 8, 2025. The analyst firm set a price target for $16.00 expecting SNDX to fall to within 12 months (a possible -0.62% downside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Syndax Pharmaceuticals (NASDAQ:SNDX) was provided by Scotiabank, and Syndax Pharmaceuticals maintained their sector perform rating.

There is no last upgrade for Syndax Pharmaceuticals

The last downgrade for Syndax Pharmaceuticals Inc happened on January 31, 2024 when Scotiabank changed their price target from $36 to $23 for Syndax Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syndax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syndax Pharmaceuticals was filed on January 8, 2025 so you should expect the next rating to be made available sometime around January 8, 2026.

While ratings are subjective and will change, the latest Syndax Pharmaceuticals (SNDX) rating was a maintained with a price target of $18.00 to $16.00. The current price Syndax Pharmaceuticals (SNDX) is trading at is $16.10, which is out of the analyst’s predicted range.